AIMS/HYPOTHESIS: The benefits of moderate alcohol consumption for type 2 diabetes have been postulated to involve a mechanism of improved insulin sensitivity. Fetuin-A, which is known to inhibit insulin signalling, has emerged as a biomarker for diabetes risk. Alcohol consumption may influence circulating fetuin-A concentrations and subsequently diabetes risk by altering the insulin signal. We therefore hypothesised that moderate alcohol consumption would be associated with lower fetuin-A concentration and that fetuin-A would partly explain the association between alcohol consumption and incident type 2 diabetes. METHODS: Among diabetes-free female participants in the Nurses' Health Study (n = 1,331), multiple linear regression was conducted to assess the association between alcohol consumption and plasma fetuin-A. Least-squares means (lsmeans) of fetuin-A were estimated in categories of alcohol consumption (0, 0.1-4.9, 5-14.9 and ≥ 15 g/day). The proportion of alcohol consumption and diabetes association explained by baseline fetuin-A was assessed in 470 matched incident diabetes case-control pairs with follow-up 2000-2006. RESULTS: Higher alcohol consumption was associated with lower plasma fetuin-A (p for trend = 0.009): lsmean ± SE 476.5 ± 5.9 μg/ml for abstainers, 468.9 ± 5.2 μg/ml for 0.1-4.9 g/day consumers, 455.9 ± 7.0 μg/ml for 5.0-14.9 g/day consumers, and 450.0 ± 9.4 μg/ml for ≥ 15.0 g/day consumers. Fetuin-A and fasting insulin explained 18.4% and 54.8%, respectively, of the inverse association between alcohol consumption and diabetes after multiple adjustment (both p for contribution <0.04). CONCLUSIONS/ INTERPRETATION: Moderate alcohol consumption is associated with lower plasma fetuin-A in diabetes-free women. Fetuin-A and insulin explain a significant proportion of the association between alcohol consumption and incident type 2 diabetes. Further studies are needed to examine potential biological mechanisms underlying this association.
AIMS/HYPOTHESIS: The benefits of moderate alcohol consumption for type 2 diabetes have been postulated to involve a mechanism of improved insulin sensitivity. Fetuin-A, which is known to inhibit insulin signalling, has emerged as a biomarker for diabetes risk. Alcohol consumption may influence circulating fetuin-A concentrations and subsequently diabetes risk by altering the insulin signal. We therefore hypothesised that moderate alcohol consumption would be associated with lower fetuin-A concentration and that fetuin-A would partly explain the association between alcohol consumption and incident type 2 diabetes. METHODS: Among diabetes-free female participants in the Nurses' Health Study (n = 1,331), multiple linear regression was conducted to assess the association between alcohol consumption and plasma fetuin-A. Least-squares means (lsmeans) of fetuin-A were estimated in categories of alcohol consumption (0, 0.1-4.9, 5-14.9 and ≥ 15 g/day). The proportion of alcohol consumption and diabetes association explained by baseline fetuin-A was assessed in 470 matched incident diabetes case-control pairs with follow-up 2000-2006. RESULTS: Higher alcohol consumption was associated with lower plasma fetuin-A (p for trend = 0.009): lsmean ± SE 476.5 ± 5.9 μg/ml for abstainers, 468.9 ± 5.2 μg/ml for 0.1-4.9 g/day consumers, 455.9 ± 7.0 μg/ml for 5.0-14.9 g/day consumers, and 450.0 ± 9.4 μg/ml for ≥ 15.0 g/day consumers. Fetuin-A and fasting insulin explained 18.4% and 54.8%, respectively, of the inverse association between alcohol consumption and diabetes after multiple adjustment (both p for contribution <0.04). CONCLUSIONS/ INTERPRETATION: Moderate alcohol consumption is associated with lower plasma fetuin-A in diabetes-freewomen. Fetuin-A and insulin explain a significant proportion of the association between alcohol consumption and incident type 2 diabetes. Further studies are needed to examine potential biological mechanisms underlying this association.
Authors: Joanne Kotsopoulos; Shelley S Tworoger; Hannia Campos; Fung-Lung Chung; Charles V Clevenger; Adrian A Franke; Christos S Mantzoros; Vincent Ricchiuti; Walter C Willett; Susan E Hankinson; A Heather Eliassen Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-03-23 Impact factor: 4.254
Authors: A Moriya; Y Iwasaki; S Ohguchi; E Kayashima; T Mitsumune; H Taniguchi; F Ikeda; Y Shiratori; K Yamamoto Journal: Aliment Pharmacol Ther Date: 2010-12-01 Impact factor: 8.171
Authors: Dolly O Baliunas; Benjamin J Taylor; Hyacinth Irving; Michael Roerecke; Jayadeep Patra; Satya Mohapatra; Jürgen Rehm Journal: Diabetes Care Date: 2009-11 Impact factor: 17.152
Authors: Joline W J Beulens; Eric B Rimm; Frank B Hu; Henk F J Hendriks; Kenneth J Mukamal Journal: Diabetes Care Date: 2008-07-15 Impact factor: 19.112
Authors: Stefanie N Hinkle; Wei Bao; Jing Wu; Yangbo Sun; Sylvia H Ley; Deirdre K Tobias; Frank Qian; Shristi Rawal; Yeyi Zhu; Jorge E Chavarro; Frank B Hu; Cuilin Zhang Journal: JAMA Netw Open Date: 2021-09-01